ICLR vs IOVA
ICON Public Limited Company vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
ICLR
ICON Public Limited Company
68
Buy
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | ICLR | IOVA |
|---|
| AI Score |
68
|
67
|
| Price |
$163.01
|
$6.99
|
| P/E Ratio |
39.04×
|
-9.31×
|
| ROE |
2.5%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
21.8%
|
116.3%
|
| Debt / Equity |
0.37×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.0
|
73.2
|
| Beta |
1.203
|
0.701
|
| Expected Upside |
+17.5%
|
—
|
AI Committee View
Current Innellis committee reasoning for ICLR versus IOVA.
ICLR leads by 1 points.
ICLR scores 68/100 (Buy) versus IOVA at 67/100 (Buy).
ICLR Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
IOVA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 73 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical